Shanghai-based NK Celltech and RongCan Biotech have entered into a partnership agreement to establish a long-term collaboration in the field of LNP delivery systems, aiming to bolster the clinical application of mRNA on NK cell therapy. The financial details of the agreement have not been disclosed.
Complementary Expertise and Platforms
NK Celltech brings to the table its proprietary “off-the-shelf” ABCDE-NK industrial production platform, which is designed to enhance the efficiency and scalability of NK cell therapies. RongCan Biotech, a nucleic acid drug developer, contributes its expertise with multiple extrahepatic targeted delivery systems and new formulations, including inhaled and lyophilized formulations, which are crucial for the effective delivery of mRNA therapies.
Enhancing Clinical Applications
This strategic partnership combines the strengths of both companies to advance the clinical application of mRNA in NK cell therapy. The collaboration aims to leverage the latest advancements in mRNA technology and LNP delivery systems to improve the efficacy and accessibility of NK cell therapies, potentially transforming the treatment landscape for various diseases.-Fineline Info & Tech
